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Introduction  
This guideline covers the assessment and management of adults and young 
people (aged 14 years and older) who have a clinical diagnosis of psychosis 
with coexisting substance misuse. 
The term psychosis is used to describe a group of severe mental health 
disorders characterised by the presence of delusions and hallucinations that 
disrupt a person’s perception, thoughts, emotions and behaviour. The main 
forms of psychosis are schizophrenia (including schizoaffective disorder, 
schizophreniform disorder and delusional disorder), bipolar disorder or other 
affective psychosis.  
Substance misuse is a broad term encompassing, in this guideline, the 
harmful use of any psychotropic substance, including alcohol and either legal 
or illicit drugs. Such use is usually, but not always, regarded as a problem if 
there is evidence of dependence, characterised by psychological 
reinforcement of repeated substance-taking behaviour and, in some cases, a 
withdrawal syndrome. However, substance misuse can be harmful without 
dependence, especially among people with a coexisting psychosis. 
Approximately 40% of people with psychosis misuse substances at some 
point in their lifetime, at least double the rate seen in the general population. 
In addition, people with coexisting substance misuse have a higher risk of 
relapse and hospitalisation, and have higher levels of unmet needs compared 
with other inpatients with psychosis who do not misuse substances. 
Substance misuse among individuals with psychiatric disorders is associated 
with significantly poorer outcomes than for individuals with a single disorder. 
These outcomes include worsening psychiatric symptoms, poorer physical 
health, increased use of institutional services, poor medication adherence, 
homelessness, increased risk of HIV infection, greater dropout from services 
and higher overall treatment costs. Social outcomes are also significantly 
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worse, including greater homelessness and rooflessness1
People with psychosis commonly take various non-prescribed substances as 
a way of coping with their symptoms, and in a third of people with psychosis, 
this amounts to harmful or dependent use. The outcome for people with 
psychosis and coexisting substance misuse is worse than for people without 
coexisting substance misuse, partly because the substances used may 
exacerbate the psychosis and partly because substances often interfere with 
pharmacological or psychological treatment. This guideline aims to help 
healthcare professionals guide people with psychosis and coexisting 
substance misuse to stabilise, reduce or stop their substance misuse, to 
improve treatment adherence and outcomes, and to enhance their lives.  
, a higher impact on 
families and carers, and increased contact with the criminal justice system. 
As well as primary and secondary services, this guideline also applies to 
services that are delivered by the third sector and commissioned by the NHS.   
                                                 
1 Rooflessness here refers to living rough or on the streets, whereas homelessness 
encompasses people who are living in shelters. 
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Person-centred care 
This guideline offers best practice advice on the assessment and 
management of people with psychosis and coexisting substance misuse.  
Treatment and care should take into account people’s needs and preferences. 
People with psychosis and coexisting substance misuse should have the 
opportunity to make informed decisions about their care and treatment, in 
partnership with their healthcare professionals. If people do not have the 
capacity to make decisions, healthcare professionals should follow the 
Department of Health’s advice on consent (available from 
www.dh.gov.uk/consent) and the code of practice that accompanies the 
Mental Capacity Act (summary available from www.publicguardian.gov.uk). In 
Wales, healthcare professionals should follow advice on consent from the 
Welsh Assembly Government (available from www.wales.nhs.uk/consent).  
If the person is under 16, healthcare professionals should follow the 
guidelines in ‘Seeking consent: working with children’ (available from 
www.dh.gov.uk/consent).  
Good communication between healthcare professionals and service users is 
essential. It should be supported by evidence-based written information 
tailored to the person’s needs. Treatment and care, and the information 
people are given about it, should be culturally appropriate. It should also be 
accessible to people with additional needs such as physical, sensory or 
learning disabilities, and to people who do not speak or read English. 
If the person agrees, families and carers should have the opportunity to be 
involved in decisions about treatment and care. Families and carers should 
also be given the information and support they need.  
Care of young people in transition between child and adolescent mental 
health services (CAMHS), and adult services should be planned and 
managed according to the best practice guidance described in ‘Transition: 
getting it right for young people’ (available from www.dh.gov.uk). 
Adult and CAMHS healthcare teams should work jointly to provide 
assessment and services to young people with psychosis and coexisting 
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substance misuse. Diagnosis and management should be reviewed 
throughout the transition process, and there should be clarity about who is the 
lead clinician to ensure continuity of care.  
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Key priorities for implementation 
Working with adults and young people with psychosis and coexisting 
substance misuse 
• When working with adults and young people with known or suspected 
psychosis and coexisting substance misuse, take time to engage the 
person from the start, and build a respectful, trusting, non-judgemental 
relationship in an atmosphere of hope and optimism. Be direct in your 
communications, use a flexible and motivational approach, and take into 
account that: 
− stigma and discrimination are associated with both psychosis and 
substance misuse 
− some people will try to conceal either one or both of their conditions  
− many people with psychosis and coexisting substance misuse fear being 
detained or imprisoned, being given psychiatric medication forcibly or 
having their children taken into care, and some fear that they may be 
‘mad’. 
Recognition of psychosis with coexisting substance misuse in adults 
and young people 
• Healthcare professionals in all settings, including primary care, secondary 
care mental health services, CAMHS and accident and emergency 
departments, and those in prisons and criminal justice mental health liaison 
schemes, should routinely ask adults and young people with known or 
suspected psychosis about their use of alcohol and/or prescribed and non-
prescribed (including illicit) drugs. If the person has used substances ask 
them about all of the following: 
− particular substance(s) used 
− quantity, frequency and pattern of use 
− route of administration 
− duration of current level of use. 
In addition, conduct an assessment of dependency (see ‘Drug misuse: opioid 
detoxification’ [NICE clinical guideline 52] and ‘Alcohol use disorders: 
diagnosis, assessment and management of harmful drinking and alcohol 
dependence’ [NICE clinical guideline 115]) and also seek corroborative 
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evidence from families, carers or significant others2
Secondary care mental health services 
, where this is possible 
and permission is given. 
Competence 
• Healthcare professionals working within secondary care mental health 
services should ensure they are competent in the recognition, treatment 
and care of adults and young people with psychosis and coexisting 
substance misuse. 
Pathways into care 
• Do not exclude adults and young people with psychosis and coexisting 
substance misuse from age-appropriate mental healthcare because of their 
substance misuse. 
• Do not exclude adults and young people with psychosis and coexisting 
substance misuse from age-appropriate substance misuse services 
because of a diagnosis of psychosis.  
Coordinating care 
• Consider seeking specialist advice and initiating joint working 
arrangements with specialist substance misuse services for adults and 
young people with psychosis being treated by community mental health 
teams, and known to be:  
− severely dependent on alcohol or 
− dependent on both alcohol and benzodiazepines or 
− dependent on opioids and/or cocaine or crack cocaine.  
Adult community mental health services or CAMHS should continue to 
provide care coordination and treatment for the psychosis within joint 
working arrangements. 
Substance misuse services 
Competence 
• Healthcare professionals in substance misuse services should be 
competent to: 
                                                 
2 ‘Significant other’ refers not just to a partner but also to friends and any person the service 
user considers to be important to them. 
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− recognise the signs and symptoms of psychosis 
− undertake a mental health needs and risk assessment sufficient to know 
how and when to refer to secondary care mental health services.  
Inpatient mental health services 
Substance misuse  
• All inpatient mental health services should ensure that they have policies 
and procedures for promoting a therapeutic environment free from drugs 
and alcohol that have been developed together with service users and their 
families, carers or significant others2. These should include: search 
procedures, visiting arrangements, planning and reviewing leave, drug and 
alcohol testing, disposal of legal and illicit substances, and other security 
measures. Soon after admission, provide all service users, and their 
families, carers or significant others2
Specific issues for young people with psychosis and coexisting 
substance misuse 
, with information about the policies 
and procedures.  
Assessment and treatment  
• Those providing and commissioning services should ensure that: 
− age-appropriate mental health services are available for young people 
with psychosis and coexisting substance misuse and 
− transition arrangements to adult mental health services are in place 
where appropriate.  
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1 Guidance 
The following guidance is based on the best available evidence. The full 
guideline (www.nice.org.uk/guidance/CG120/Guidance) gives details of the 
methods and the evidence used to develop the guidance. 
1.1 Principles of care 
Working with adults and young people with psychosis and coexisting 
substance misuse 
1.1.1 When working with adults and young people with known or 
suspected psychosis and coexisting substance misuse, take time to 
engage the person from the start, and build a respectful, trusting, 
non-judgemental relationship in an atmosphere of hope and 
optimism. Be direct in your communications, use a flexible and 
motivational approach, and take into account that: 
• stigma and discrimination are associated with both psychosis 
and substance misuse 
• some people will try to conceal either one or both of their 
conditions  
• many people with psychosis and coexisting substance misuse 
fear being detained or imprisoned, being given psychiatric 
medication forcibly or having their children taken into care, and 
some fear that they may be ‘mad’.  
1.1.2 When working with adults and young people with known or 
suspected psychosis and coexisting substance misuse: 
• ensure that discussions take place in settings in which 
confidentiality, privacy and dignity can be maintained 
• avoid clinical language without adequate explanation  
• provide independent interpreters (who are not related to the 
person) if needed 
• aim to preserve continuity of care and minimise changes of key 
workers in order to foster a therapeutic relationship.  
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Race and culture  
1.1.3 Healthcare professionals working with adults and young people 
with psychosis and coexisting substance misuse should ensure that 
they are competent to engage, assess, and negotiate with service 
users from diverse cultural and ethnic backgrounds and their 
families, carers or significant others3
1.1.4 Work with local black and minority ethnic organisations and groups 
to help support and engage adults and young people with 
psychosis and coexisting substance misuse. Offer organisations 
and groups information and training about how to recognise 
psychosis with coexisting substance misuse and access treatment 
and care locally. 
. 
Providing information 
1.1.5 Offer written and verbal information to adults and young people 
appropriate to their level of understanding about the nature and 
treatment of both their psychosis and substance misuse. Written 
information should: 
• include the ‘Understanding NICE guidance’ booklet4
• be available in the appropriate language or, for those who 
cannot use written text, in an alternative format (audio or video).  
, which 
contains a list of organisations that can provide more information 
(see section 5.3) 
1.1.6 All healthcare professionals in primary, secondary or specialist 
substance misuse services working with adults and young people 
with psychosis should offer information and advice about the risks 
associated with substance misuse and the negative impact that it 
can have on the experience and management of psychosis. 
Working with and supporting families, carers and significant others
1.1.7 Encourage families, carers or significant others
3 
3
                                                 
3 ‘Significant other’ refers not just to a partner but also to friends and any person the service 
user considers to be important to them. 
 to be involved in 
the treatment of adults and young people with psychosis and 
4 Available in English and Welsh from www.nice.org.uk/guidance/CG120 
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coexisting substance misuse to help support treatment and care 
and promote recovery. 
1.1.8 When families, carers or significant others3
1.1.9 When families, carers or significant others
 live or are in close 
contact with the person with psychosis and coexisting substance 
misuse, offer family intervention as recommended in 
‘Schizophrenia: core interventions in the treatment and 
management of schizophrenia in adults in primary and secondary 
care’ (NICE clinical guideline 82). 
3
1.1.10 Offer families, carers or significant others
 are involved in 
supporting the person with psychosis and coexisting substance 
misuse, discuss with them any concerns about the impact of these 
conditions on them and on other family members. 
3
1.1.11 Offer written and verbal information to families, carers or significant 
others
 a carer’s assessment of 
their caring, physical, social, and mental health needs. Where 
needs are identified, develop a care plan for the family member or 
carer. 
3
1.1.12 Offer information to families, carers or significant others
 appropriate to their level of understanding about the nature 
and treatment of psychosis and substance misuse, including how 
they can help to support the person. Written information should be 
available in the appropriate language or, for those who cannot use 
written text, in an accessible format (audio or video). 
3 about 
local family or carer support groups and voluntary organisations, 
including those for psychosis and for substance misuse, and help 
families, carers or significant others3
1.1.13 Negotiate confidentiality and sharing of information between the 
person with psychosis and coexisting substance misuse and their 
family, carer or a significant other
 to access these.   
3
1.1.14 Ensure the needs of young carers or dependent adults of the 
person with psychosis and coexisting substance misuse are 
. 
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assessed. Initiate safeguarding procedures where appropriate (see 
recommendations 1.1.16–1.1.20). 
Support for healthcare professionals 
1.1.15 Working with people with psychosis and coexisting substance 
misuse can be challenging and healthcare professionals should 
seek effective support – for example, through professional 
supervision or staff support groups. 
Safeguarding issues 
1.1.16 If people with psychosis and coexisting substance misuse are 
parents or carers of children or young people, ensure that the 
child’s or young person’s needs are assessed according to local 
safeguarding procedures5
1.1.17 If children or young people being cared for by people with 
psychosis and coexisting substance misuse are referred to CAMHS 
under local safeguarding procedures: 
.  
• use a multi-agency approach, including social care and 
education, to ensure that various perspectives on the child’s life 
are considered 
• consider using the Common Assessment Framework6
1.1.18 If serious concerns are identified, health or social care 
professionals working with the child or young person (see 
recommendation 1.1.17) should develop a child protection plan. 
; advice on 
this can be sought from the local named lead for safeguarding.  
1.1.19 When working with people with psychosis and coexisting substance 
misuse who are responsible for vulnerable adults, ensure that the 
home situation is risk assessed and that safeguarding procedures 
are in place for the vulnerable adult. Advice on safeguarding 
vulnerable adults can be sought from the local named lead for 
safeguarding.  
                                                 
5 www.safeguardingchildren.org.uk 
6 www.cwdcouncil.org.uk/caf 
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1.1.20 Consider adults with psychosis and coexisting substance misuse 
for assessment according to local safeguarding procedures for 
vulnerable adults if there are concerns regarding exploitation or 
self-care, or if they have been in contact with the criminal justice 
system. 
Consent, capacity and treatment decisions 
1.1.21 Before undertaking any investigations for substance misuse, and 
before each treatment decision is taken: 
• provide service users with full information appropriate to their 
needs about psychosis and substance misuse and the 
management of both conditions, to ensure informed consent  
• understand and apply the principles underpinning the Mental 
Capacity Act (2005), and be aware that mental capacity is 
decision-specific (that is, if there is doubt about mental capacity, 
assessment of mental capacity should be made in relation to 
each decision) 
• be able to assess mental capacity using the test set out in the 
Mental Capacity Act (2005). 
These principles should apply whether or not people are being 
detained or treated under the Mental Health Act (1983; amended 
1995 and 2007). 
Advance decisions and statements 
1.1.22 Develop advance decisions and advance statements in 
collaboration with adults with psychosis and coexisting substance 
misuse, especially if their condition is severe and they have been 
treated under the Mental Health Act (1983; amended 1995 and 
2007). Record the decisions and statements and include copies in 
the care plan in primary and secondary care. Give copies to the 
person, their care coordinator, and their family, carer or a 
significant other3
1.1.23 Take advance decisions and advance statements into account in 
accordance with the Mental Capacity Act (2005). Although advance 
 if the person agrees. 
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decisions and advance statements can be overridden using the 
Mental Health Act (1983; amended 1995 and 2007), try to honour 
them wherever possible. 
Working with the voluntary sector 
1.1.24 Healthcare professionals in primary care and secondary care 
mental health services, and in specialist substance misuse 
services, should work collaboratively with voluntary sector 
organisations that provide help and support for adults and young 
people with psychosis and coexisting substance misuse. Ensure 
that advocates from such organisations are included in the care 
planning and care programming process wherever this is possible 
and agreed by the person with psychosis and coexisting substance 
misuse. 
1.1.25 Healthcare professionals in primary care and secondary care 
mental health services, and in specialist substance misuse 
services, should work collaboratively with voluntary sector 
organisations providing services for adults and young people with 
psychosis and coexisting substance misuse to develop agreed 
protocols for routine and crisis care.  
1.2 Recognition of psychosis with coexisting substance 
misuse  
1.2.1 Healthcare professionals in all settings, including primary care, 
secondary care mental health services, CAMHS and accident and 
emergency departments, and those in prisons and criminal justice 
mental health liaison schemes, should routinely ask adults and 
young people with known or suspected psychosis about their use of 
alcohol and/or prescribed and non-prescribed (including illicit) 
drugs. If the person has used substances ask them about all of the 
following: 
• particular substance(s) used 
• quantity, frequency and pattern of use 
• route of administration  
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• duration of current level of use. 
In addition, conduct an assessment of dependency (see ‘Drug 
misuse: opioid detoxification’ [NICE clinical guideline 52] and 
‘Alcohol use disorders: diagnosis, assessment and management of 
harmful drinking and alcohol dependence’ [NICE clinical guideline 
115]) and also seek corroborative evidence from families, carers or 
significant others3
1.2.2.       Healthcare professionals in all settings, including primary care, 
secondary care mental health services, CAMHS and accident and 
emergency departments, and those in prisons and criminal justice 
mental health liaison schemes, should routinely assess adults and 
young people with known or suspected substance misuse for 
possible psychosis. Seek corroborative evidence from families, 
carers or significant others
, where this is possible and permission is given.  
3
1.3 Primary care 
, where this is possible and permission 
is given. 
Referral from primary care 
1.3.1 Refer all adults and young people with psychosis or suspected 
psychosis, including those who are suspected of coexisting 
substance misuse, to either secondary care mental health services 
or CAMHS for assessment and further management. 
1.3.2 Refer all adults and young people with substance misuse or 
suspected substance misuse who are suspected of having 
coexisting psychosis to secondary care mental health services or 
CAMHS for assessment and further management. 
Physical healthcare 
1.3.3 Monitor the physical health of adults and young people with 
psychosis and coexisting substance misuse, as described in the 
guideline on schizophrenia (NICE clinical guideline 82). Pay 
particular attention to the impact of alcohol and drugs (prescribed 
and non-prescribed) on physical health. Monitoring should be 
conducted at least once a year or more frequently if the person has 
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a significant physical illness or there is a risk of physical illness 
because of substance misuse. 
1.4 Secondary care mental health services 
Competence 
1.4.1 Healthcare professionals working within secondary care mental 
health services should ensure they are competent in the 
recognition, treatment and care of adults and young people with 
psychosis and coexisting substance misuse.  
1.4.2 Healthcare professionals working within secondary care mental 
health services with adults and young people with psychosis and 
coexisting substance misuse should consider having supervision, 
advice, consultation and/or training from specialists in substance 
misuse services. This is to aid in the development and 
implementation of treatment plans for substance misuse within 
CAMHS or adult community mental health services. 
Pathways into care 
1.4.3 Do not exclude adults and young people with psychosis and 
coexisting substance misuse from age-appropriate mental 
healthcare because of their substance misuse.  
1.4.4 Do not exclude adults and young people with psychosis and 
coexisting substance misuse from age-appropriate substance 
misuse services because of a diagnosis of psychosis.  
1.4.5 For most adults with psychosis and coexisting substance misuse, 
treatment for both conditions should be provided by healthcare 
professionals in secondary care mental health services such as 
community-based mental health teams. 
Coordinating care 
1.4.6 Consider seeking specialist advice and initiating joint working 
arrangements with specialist substance misuse services for adults 
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and young people with psychosis being treated by community 
mental health teams, and known to be:  
• severely dependent on alcohol or 
• dependent on both alcohol and benzodiazepines or 
• dependent on opioids and/or cocaine or crack cocaine. 
Adult community mental health services or CAMHS should continue 
to provide care coordination and treatment for the psychosis within 
joint working arrangements. 
1.4.7 Consider seeking specialist advice and initiate joint working 
arrangements with specialist substance misuse services if the 
person’s substance misuse: 
• is difficult to control and/or 
• leads to significant impairment of functioning, family breakdown 
or significant social disruption such as homelessness. 
1.4.8 If a person with psychosis and coexisting substance misuse 
requires planned detoxification from either drugs or alcohol, this 
should take place in an inpatient setting (see section 1.6). 
1.4.9 Delivery of care and transfer between services for adults and young 
people with psychosis and coexisting substance misuse should 
include a care coordinator and use the Care Programme Approach. 
Assessment 
1.4.10 Adults and young people with psychosis and coexisting substance 
misuse attending secondary care mental health services should be 
offered a comprehensive, multidisciplinary assessment, including 
assessment of all of the following: 
• personal history 
• mental, physical and sexual health 
• social, family and economic situation 
• accommodation, including history of homelessness and stability 
of current living arrangements 
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• current and past substance misuse and its impact upon their life, 
health and response to treatment 
• criminal justice history and current status 
• personal strengths and weaknesses and readiness to change 
their substance use and other aspects of their lives.  
The assessment may need to take place over several meetings to 
gain a full understanding of the person and the range of problems 
they experience, and to promote engagement. 
1.4.11 When assessing adults and young people with psychosis and 
coexisting substance misuse, seek corroborative evidence from 
families, carers or significant others3 where this is possible and 
permission is given. Summarise the findings, share this with the 
person and record it in their care plan. 
1.4.12 Review any changes in the person’s use of substances. This 
should include changes in: the way the use of substances affects 
the person over time 
• patterns of use 
• mental and physical state  
• circumstances and treatment.  
Share the summary with the person and record it in their care plan. 
1.4.13 When assessing adults and young people with psychosis and 
coexisting substance misuse, be aware that low levels of substance 
use that would not usually be considered harmful or problematic in 
people without psychosis, can have a significant impact on the 
mental health of people with psychosis. 
1.4.14 Regularly assess and monitor risk of harm to self and/or others and 
develop and implement a risk management plan to be reviewed 
when the service users’ circumstances or levels of risk change. 
Specifically consider additional risks associated with substance 
misuse, including: 
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• physical health risks (for example, withdrawal seizures, delirium 
tremens, blood-borne viruses, accidental overdose, and 
interactions with prescribed medication) and  
• the impact that substance use may have on other risks such as 
self-harm, suicide, self-neglect, violence, abuse of or by others, 
exploitation, accidental injury and offending behaviour.  
Biological/physical testing 
1.4.15 Biological or physical tests for substance use (such as blood and 
urine tests or hair analysis) may be useful in the assessment, 
treatment and management of substance misuse for adults and 
young people with psychosis. However, this should be agreed with 
the person first as part of their care plan. Do not use biological or 
physical tests in routine screening for substance misuse in adults 
and young people with psychosis.  
Treatment 
1.4.16 Before starting treatment for adults and young people with 
psychosis and coexisting substance misuse, review: 
•  the diagnosis of psychosis and of the coexisting substance 
misuse, especially if either diagnosis has been made during a 
crisis or emergency presentation and 
•  the effectiveness of previous and current treatments and their 
acceptability to the person; discontinue ineffective treatments. 
1.4.17 When developing a care plan for an adult or young person with 
psychosis and coexisting substance misuse, take account of the 
complex and individual relationships between substance misuse, 
psychotic symptoms, emotional state, behaviour and the person’s 
social context. 
1.4.18 Ensure that adults and young people with psychosis and coexisting 
substance misuse are offered evidence-based treatments for both 
conditions (see recommendations 1.4.19 and 1.4.20).  
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1.4.19 For the treatment of psychosis, see ‘Bipolar disorder: the 
management of bipolar disorder in adults, children and 
adolescents, in primary and secondary care’ (NICE clinical 
guideline 38) or the guideline on schizophrenia (NICE clinical 
guideline 82).  
1.4.20 For the treatment of substance misuse, see: 
• ‘Alcohol-use disorders: diagnosis and clinical management of 
alcohol-related physical complications’ and the guideline on 
alcohol dependence and harmful alcohol use (NICE clinical 
guidelines 100 and CG115) and/or  
• ‘Drug misuse: psychosocial interventions’ and the guideline on 
opioid detoxification (NICE clinical guidelines 51 and 52).  
1.4.21 When developing a treatment plan for a person with psychosis and 
coexisting substance misuse, tailor the plan and the sequencing of 
treatments to the person and take account of: 
• the relative severity of both the psychosis and the substance 
misuse at different times and 
• the person’s social and treatment context and  
• the person’s readiness for change. 
1.4.22 Do not exclude adults and young people with psychosis and 
coexisting substance misuse from contingency management 
programmes because of their psychosis. 
1.4.23 Use antipsychotics according to the guideline on schizophrenia 
(NICE clinical guideline 82) or bipolar disorder (NICE clinical 
guideline 38) because there is no evidence for any differential 
benefit for one antipsychotic over another for people with psychosis 
and coexisting substance misuse.  
1.4.24 Use depot/long-acting injectable antipsychotics according to the 
guideline on schizophrenia (NICE clinical guideline 82) in managing 
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covert non-adherence with treatment for psychosis and not as a 
specific treatment for psychosis and coexisting substance misuse. 
1.4.25 When prescribing medication for adults and young people with 
psychosis and coexisting substance misuse: 
• take into account the level and type of substance misuse, 
especially of alcohol, as this may alter the metabolism of 
prescribed medication, decrease its effectiveness and/or 
increase the risk of side effects  
• warn the person about potential interactions between 
substances of misuse and prescribed medication 
• discuss the problems and potential dangers of using non-
prescribed substances and alcohol to counteract the effects or 
side effects of prescribed medication. 
1.5 Substance misuse services 
Competence 
1.5.1 Healthcare professionals in substance misuse services should be 
competent to: 
• recognise the signs and symptoms of psychosis 
• undertake a mental health needs and risk assessment sufficient 
to know how and when to refer to secondary care mental health 
services.  
Assessment  
1.5.2 Adults and young people with psychosis and coexisting substance 
misuse attending substance misuse services should be offered a 
comprehensive, multidisciplinary mental health assessment in 
addition to an assessment of their substance misuse.  
Joint working  
1.5.3 Healthcare professionals in substance misuse services should be 
present at Care Programme Approach meetings for adults and 
young people with psychosis and coexisting substance misuse 
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within their service who are also receiving treatment and support in 
other health services.  
1.5.4 Specialist substance misuse services should provide advice, 
consultation, and training for healthcare professionals in adult 
mental health services and CAMHS regarding the assessment and 
treatment of substance misuse, and of substance misuse with 
coexisting psychosis. 
1.5.5 Specialist substance misuse services should work closely with 
secondary care mental health services to develop local protocols 
derived from this guideline for adults and young people with 
psychosis and coexisting substance misuse. The agreed local 
protocols should set out responsibilities and processes for 
assessment, referral, treatment and shared care across the whole 
care pathway. 
1.6 Inpatient mental health services 
Substance misuse  
1.6.1 All inpatient mental health services should ensure that they have 
policies and procedures for promoting a therapeutic environment 
free from drugs and alcohol that have been developed together 
with service users and their families, carers or significant others3. 
These should include: search procedures, visiting arrangements, 
planning and reviewing leave, drug and alcohol testing, disposal of 
legal and illicit substances, and other security measures. Soon after 
admission, provide all service users, and their families, carers or 
significant others3
1.6.2 When carrying out a comprehensive assessment for all adults and 
young people admitted to inpatient mental health services, ensure 
that they are assessed for current substance misuse and evidence 
of withdrawal symptoms at the point of admission. 
, with information about the policies and 
procedures.  
1.6.3 Biological or physical tests for substance use should only be 
considered in inpatient services as part of the assessment and 
 NICE clinical guideline 120 – Psychosis with coexisting substance misuse  25 
treatment planning for adults and young people with psychosis and 
coexisting substance misuse. Obtain consent for these tests and 
inform the person of the results as part of an agreed treatment 
plan. Where mental capacity is lacking, refer to the Mental Capacity 
Act (2005). 
1.6.4 Ensure that planned detoxification from either drugs or alcohol is 
undertaken only: 
• with the involvement and advice of substance misuse services 
• in an inpatient setting, preferably in specialist detoxification units,  
or designated detoxification beds within inpatient mental health 
services and  
• as part of an overall treatment plan.  
For the further management of opioid detoxification see the 
guideline on opioid detoxification (NICE clinical guideline 52). For 
the further management of assisted alcohol withdrawal see the 
guideline on alcohol dependence and harmful alcohol use (NICE 
clinical guideline 115). 
Discharge  
1.6.5 Do not discharge adults and young people with psychosis and 
coexisting substance misuse from an inpatient mental health 
service solely because of their substance misuse. 
1.6.6 When adults and young people with psychosis and coexisting 
substance misuse are discharged from an inpatient mental health 
service, ensure that they have: 
• an identified care coordinator and 
• a care plan that includes a consideration of needs associated 
with both their psychosis and their substance misuse and   
• been informed of the risks of overdose if they start reusing 
substances, especially opioids, that have been reduced or 
discontinued during the inpatient stay.  
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1.7 Staffed accommodation 
Exclusion from services 
1.7.1 Do not exclude people with psychosis and coexisting substance 
misuse from staffed accommodation (such as supported or 
residential care) solely because of their substance misuse. 
1.7.2 Do not exclude people with psychosis and coexisting substance 
misuse from staffed accommodation aimed at addressing 
substance misuse solely because of their diagnosis of psychosis. 
Aims of treatment 
1.7.3 Ensure that people with psychosis and coexisting substance 
misuse who live in staffed accommodation receive treatment for 
both their psychosis and their substance misuse with the explicit 
aim of helping the person remain in stable accommodation. 
Specific issues for young people with psychosis and 
coexisting substance misuse 
Competence 
1.8.1 Professionals in Tier 1 (primary care and educational settings) 
should be competent to recognise early signs of psychosis and 
substance misuse in young people. 
1.8.2 Healthcare professionals in Tier 3 (community mental health 
teams) and Tier 4 (specialist inpatient and regional services) 
CAMHS, and in early intervention in psychosis services, should be 
competent in the management of psychosis and substance misuse 
in young people. 
Identification and referral 
1.8.3 Professionals in Tier 1 (primary care and educational settings) 
should seek advice or consultation from Tier 2 CAMHS (primary 
care) when signs of psychosis are detected in young people. If 
healthcare professionals in Tier 2 CAMHS detect signs of 
psychosis in young people, a referral to Tier 3 CAMHS or early 
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intervention in psychosis services for young people should be 
made according to local protocols. 
1.8.4 Ask all young people seen in Tier 3 and Tier 4 CAMHS and in early 
intervention in psychosis services who have psychosis or 
suspected psychosis about substance misuse (see 
recommendation 1.2.1). 
1.8.5 Children and young people who, after comprehensive assessment, 
are considered to be at high risk of harm to themselves or others, 
should be referred directly to Tier 4 CAMHS including inpatient 
services where necessary. 
Assessment and treatment  
1.8.6 Healthcare professionals working with young people with psychosis 
and coexisting substance misuse should ensure they are familiar 
with the legal framework that applies to young people including the 
Mental Health Act (1983; amended 1995 and 2007), the Mental 
Capacity Act (2005), and the Children Act (2004). 
1.8.7 For psychological, psychosocial, family and medical interventions 
for young people, follow the recommendations for adults in this 
guideline; they may need to be adapted according to the young 
person’s circumstances and age. In addition, other agencies, 
including children’s services, should be involved to ensure that the 
young person's educational, employment, family and housing 
needs are met. 
1.8.8 When prescribing medication, take into account the young person’s 
age and weight when determining the dose. If it is appropriate to 
prescribe unlicensed medication, explain to the young person 
and/or their parents or carers the reasons for doing this. 
1.8.9 Those providing and commissioning services should ensure that: 
• age-appropriate mental health services are available for young 
people with psychosis and coexisting substance misuse and 
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• transition arrangements to adult mental health services are in 
place where appropriate.  
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2 Notes on the scope of the guidance 
NICE guidelines are developed in accordance with a scope that defines what 
the guideline will and will not cover. The scope of this guideline is available 
from www.nice.org.uk/guidance/CG120 – click on ‘How this guidance was 
produced’. 
How this guideline was developed 
NICE commissioned the National Collaborating Centre for Mental Health to 
develop this guideline. The Centre established a Guideline Development 
Group (see appendix A), which reviewed the evidence and developed the 
recommendations. An independent guideline review panel oversaw the 
development of the guideline (see appendix B). 
There is more information about how NICE clinical guidelines are developed 
on the NICE website (www.nice.org.uk/HowWeWork). A booklet, ‘How NICE 
clinical guidelines are developed: an overview for stakeholders, the public and 
the NHS’ (fourth edition, published 2009), is available from NICE publications 
(phone 0845 003 7783 or email publications@nice.org.uk and quote reference 
N1739). 
3 Implementation  
NICE has developed tools to help organisations implement this guidance (see 
www.nice.org.uk/guidance/CG120).  
4 Research recommendations 
The Guideline Development Group has made the following recommendations 
for research, based on its review of evidence, to improve NICE guidance and 
patient care in the future. The Guideline Development Group’s full set of 
research recommendations is detailed in the full guideline (see section 5).  
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4.1 Determining prevalence, risk and protective factors, and 
course of illness  
What are the prevalence, risk and protective factors, and course of illness for 
different combinations of psychosis and coexisting substance misuse (for 
example, schizophrenia and cannabis misuse or bipolar disorder and alcohol 
misuse)? 
Why this is important 
Studies vary in terms of the definitions and diagnosis of psychosis and 
substance misuse, and how they are conducted. This makes it difficult to draw 
conclusions about prevalence and patterns in patient groups differentiated by 
diagnosis, ethnicity and other demographics. Additionally, most studies are 
cross-sectional, so little is known about how both conditions change over time.  
Moreover, there is little guidance about which levels and patterns of 
substance misuse in which patient groups are associated with the worst 
clinical and social outcomes. Such information is necessary to target 
resources at groups most at risk of very poor outcomes.  
This question should be answered using a longitudinal study design with a 
representative sample large enough to establish the prevalence, pattern, and 
epidemiology of different combinations of psychosis and coexisting substance 
misuse, associated social determinants, treatment and outcome. The study 
should also collect information that could inform the development of new 
interventions or the modification of existing interventions to improve 
prognosis. 
4.2 Predicting the onset of substance misuse in young 
people with psychosis 
What risk factors predict the onset of substance misuse in young people with 
psychosis? 
Why this is important 
People with psychosis and coexisting substance misuse are more likely to be 
non-adherent to prescribed medication, and have poor engagement with 
treatment programmes, increased risk of suicide, more and longer inpatient 
stays, increased risk of violence and time spent in the criminal justice system, 
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and poorer overall prognosis. Because the onset of psychosis at a younger 
age is also an indicator of poor prognosis, people with a combination of 
younger age of onset and coexisting substance misuse may have a 
particularly poor prognosis. A clearer understanding of the risk and protective 
factors for substance misuse in young people with psychosis, and the 
interrelationship of the two conditions over time, may facilitate the 
development of treatment approaches for the coexisting conditions in this 
group. This may then improve the longer term outcome for a group of people 
who tend to have a poor prognosis.  
This question should be answered using a prospective cohort study design. 
4.3 Psychosocial interventions versus standard care  
Are psychosocial interventions clinically and cost effective when compared 
with standard care for people with psychosis and coexisting substance 
misuse? 
Why this is important 
Psychosocial interventions are recommended for the treatment of substance 
misuse, with contingency management showing particular promise. However, 
they have not been adequately tested in people who also have psychosis. 
This question should be answered using a randomised controlled trial that 
examines short- and medium-term outcomes over at least 18 months. Studies 
should focus on people whose misuse of substances is most often 
encountered in clinical practice and has the greatest impact on mental health 
(such as cannabis and polysubstance misuse) and on  those interventions – 
such as contingency management, cognitive therapy and relapse prevention – 
that show most promise in people with substance misuse without psychosis. 
Those providing the intervention should be trained and supervised to ensure 
that the results are robust and generalisable. Outcomes should reflect both 
observer and service user-rated assessments of improvement (including 
mental health and social functioning) and the intervention’s acceptability. 
Studies need to be large enough to determine the intervention’s costs and 
cost effectiveness. 
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4.4 Environmental interventions versus standard care  
Are environmental interventions clinically and cost effective when compared 
with standard care for people with psychosis and coexisting substance 
misuse? 
Why this is important 
Social and other environmental factors can play a role in triggering and 
maintaining substance misuse in people with psychosis, and in reducing the 
likelihood of progress and recovery. Evidence suggests that when the primary 
focus of management involves improving the environment, both conditions 
may improve.  
This question should be answered using a randomised controlled trial that 
examines short- and medium-term outcomes over at least 12 months. Studies 
should focus on people with psychosis whose misuse of substances is most 
often encountered in clinical practice and has the greatest impact on mental 
health (such as cannabis and polysubstance misuse), and on interventions 
that take a collaborative approach to identifying and modifying social and 
environmental factors that may trigger substance misuse. Those providing the 
intervention should be trained and supervised to ensure that the results are 
robust and generalisable. Outcomes should reflect both observer and service 
user-rated assessments of improvement (including mental health and social 
functioning) and the intervention’s acceptability. Studies need to be large 
enough to determine the intervention’s costs and cost effectiveness. 
4.5  Clozapine versus other pharmacological interventions  
Is clozapine clinically and cost effective when compared with other 
pharmacological interventions for people with psychosis and coexisting 
substance misuse? 
Why this is important 
The NICE guideline on schizophrenia (NICE clinical guideline 82) states that 
clozapine should be offered to people with schizophrenia whose illness has 
not responded adequately to treatment despite the sequential use of adequate 
doses of at least two different antipsychotic drugs. However, there is 
insufficient evidence to guide healthcare professionals about the use of 
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clozapine in people with psychosis and coexisting substance misuse. Expert 
opinion often advocates clozapine as having a particular role in this 
population, but the evidence to support such statements is lacking. Clozapine 
is expensive and has a wide range of side effects, some of which may be life-
threatening if not monitored correctly.  
This question should be answered using a randomised controlled trial in which 
participants are stratified for presenting problem. It should report short- and 
longer-term outcomes (including substance misuse, acceptability of the 
intervention, and cost effectiveness) of at least 12 months’ duration. 
5 Other versions of this guideline 
5.1 Full guideline 
The full guideline, Psychosis with coexisting substance misuse: assessment 
and management in adults and young people’, contains details of the methods 
and evidence used to develop the guideline. It is published by the National 
Collaborating Centre for Mental Health, and is available from our website 
(www.nice.org.uk/guidance/CG120/Guidance).  
5.2 Quick reference guide 
A quick reference guide for healthcare professionals is available from 
www.nice.org.uk/guidance/CG120/QuickRefGuide  
For printed copies, phone NICE publications on 0845 003 7783 or email 
publications@nice.org.uk (quote reference number N2469).  
5.3 ‘Understanding NICE guidance’ 
A summary for service users and carers (‘Understanding NICE guidance’) is 
available from www.nice.org.uk/guidance/CG120/PublicInfo 
For printed copies, phone NICE publications on 0845 003 7783 or email 
publications@nice.org.uk (quote reference number N2470).  
We encourage NHS and voluntary sector organisations to use text from this 
booklet in their own information about psychosis with coexisting substance 
misuse. 
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6 Related NICE guidance 
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• Community-based interventions to reduce substance misuse among 
vulnerable and disadvantaged children and young people. NICE public 
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appraisal guidance 115 (2007). Available from 
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www.nice.org.uk/guidance/CG38 
• Violence. NICE clinical guideline 25 (2005). Available from 
www.nice.org.uk/guidance/CG25 
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7 Updating the guideline 
NICE clinical guidelines are updated so that recommendations take into 
account important new information. New evidence is checked 3 years after 
publication, and healthcare professionals and patients are asked for their 
views; we use this information to decide whether all or part of a guideline 
needs updating. If important new evidence is published at other times, we 
may decide to do a more rapid update of some recommendations. Please see 
our website for information about updating the guideline. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 NICE clinical guideline 120 – Psychosis with coexisting substance misuse  36 
Appendix A: The Guideline Development Group, 
National Collaborating Centre and NICE project team 
Guideline Development Group 
Professor Peter Tyrer (Chair, Guideline Development Group) 
Professor of Community Psychiatry, Imperial College, London 
Professor Tim Kendall (Facilitator, Guideline Development Group) 
Director, National Collaborating Centre for Mental Health (NCCMH) 
Medical Director, Sheffield Health and Social Care Trust  
Consultant Adult Psychiatrist 
Professor Mohammed T Abou-Saleh  
Professor of Psychiatry, St George’s, University of London and Honorary 
Consultant in Addiction Psychiatry, South West London and St George’s 
Mental Health NHS Trust, London 
Professor Christine Barrowclough 
Professor of Clinical Psychology, University of Manchester 
Ms Tina Braithwaite  
Patient and carer member, Director of Service User Involvement, Revolving 
Doors Agency 
Dr Andy Cotgrove 
Young people (CAMHS level 4), Pine Lodge Young People’s Centre, Chester 
Dr Mike Crawford 
Reader in Mental Health Services Research, Imperial College London/Central 
and North West London Mental Health NHS Trust 
Professor Ilana Crome  
Professor of Addiction Psychiatry, Keele University Medical School  
Honorary Consultant Addiction Psychiatrist, South Staffordshire and 
Shropshire NHS Foundation Trust 
Mr Matthew Dyer  
Health Economist, NCCMH 
 NICE clinical guideline 120 – Psychosis with coexisting substance misuse  37 
Mr Mike Firn 
Clinical Service Development Lead, South West London and St George’s 
Mental Health NHS Trust  
Dr Frank Holloway 
Consultant Psychiatrist and Clinical Director, Bethlem Royal Hospital 
Dr Cheryl Kipping  
Nurse Consultant, South London and Maudsley NHS Foundation Trust 
Ms Katherine Leggett 
Guideline Development Manager, NCCMH 
Dr Kate McKinnell  
Senior Medical Officer (Addictions), Sefton Integrated Recovery Team (Crime 
Reduction Initiatives) 
Dr Jonathan Mitchell  
Consultant Psychiatrist, Early Intervention and Continuing Needs Services, 
Sheffield Health and Social Care Trust  
Dr David Ndegwa  
Consultant Forensic Psychiatrist/Strategy Director, South London and 
Maudsley NHS Foundation Trust 
Mr Peter Pratt  
Chief Pharmacist, Sheffield Health and Social Care Trust/Rotherham 
Doncaster and South Humber NHS Trust 
Ms Theresa Renwick  
Social Care Lead for Mental Health, Royal Borough of Kensington and 
Chelsea 
Ms Laura Shields  
Research Assistant, NCCMH 
Mr Leroy Simpson  
Patient and carer member 
Board Member, Salvation Army Housing Association 
 NICE clinical guideline 120 – Psychosis with coexisting substance misuse  38 
Ms Sarah Stockton  
Senior Information Scientist, NCCMH  
Dr Clare Taylor 
Editor, NCCMH 
Dr Craig Whittington  
Senior Systematic Reviewer, NCCMH 
Mrs Penelope Wigram  
Patient and carer member 
Psychoanalytic Psychotherapist, British Psychoanalytic Council 
NICE project team 
Sharon Summers-Ma 
Associate Director 
Caroline Keir 
Guideline Commissioning Manager 
Nick Staples 
Guideline Coordinator 
Nichole Taske 
Technical Lead 
Stefanie Reken 
Health Economist 
Annette Mead 
Editor 
 
 
 
 NICE clinical guideline 120 – Psychosis with coexisting substance misuse  39 
Appendix B: The Guideline Review Panel 
The Guideline Review Panel is an independent panel that oversees the 
development of the guideline and takes responsibility for monitoring 
adherence to NICE guideline development processes. In particular, the panel 
ensures that stakeholder comments have been adequately considered and 
responded to. The panel includes members from the following perspectives: 
primary care, secondary care, lay, public health and industry.  
Dr Robert Walker (Chair) 
General Practitioner, Workington 
Mr Robin Beal 
Consultant in Accident and Emergency Medicine, Isle of Wight 
Dr Mark Hill 
Head of Medical Affairs, Novartis Pharmaceuticals Ltd 
Dr John Harley 
Clinical Governance and Prescribing Lead and General Practitioner, North 
Tees PCT 
Mrs Ailsa Donnelly 
Lay member 
